Tatsis Ourania insider trades
Tatsis Ourania has filed 41 Form 4s with the SEC that we hold, for Vertex Pharmaceuticals INC / Ma (VRTX) (EVP, Chief Reg. & Quality Off.), VERV (Director) and Odyssey Therapeutics, Inc. (ODTX) (Director). Across all of them we count 0 purchases worth $0 and 60 sales worth $19.1M reported on Form 4. In the last 12 months: 0 purchases ($0) and 8 sales ($6.5M). The largest single trade was a sale of 4,500 shares of Vertex Pharmaceuticals INC / Ma worth $2.1M, dated 2026-01-07. The first filing on our record is dated 2022-02-03 and the latest 2026-07-23.
Vertex Pharmaceuticals INC / Ma (VRTX)
| Trade date | Code | Shares | Value as filed | Filed | Source |
|---|---|---|---|---|---|
| 2022-02-11 | S, sale reported on Form 4 | 100 | $23.4K | 2022-02-14 | SEC |
| 2022-02-11 | S, sale reported on Form 4 | 78 | $18.3K | 2022-02-14 | SEC |
| 2022-02-11 | S, sale reported on Form 4 | 70 | $16.5K | 2022-02-14 | SEC |
| 2022-02-11 | S, sale reported on Form 4 | 42 | $9.9K | 2022-02-14 | SEC |
| 2022-02-18 | S, sale reported on Form 4 | 120 | $28.0K | 2022-02-22 | SEC |
| 2022-02-18 | S, sale reported on Form 4 | 80 | $18.6K | 2022-02-22 | SEC |
| 2022-02-18 | S, sale reported on Form 4 | 218 | $50.0K | 2022-02-22 | SEC |
| 2022-02-18 | S, sale reported on Form 4 | 101 | $23.3K | 2022-02-22 | SEC |
| 2022-02-25 | S, sale reported on Form 4 | 77 | $17.7K | 2022-02-28 | SEC |
| 2022-02-25 | S, sale reported on Form 4 | 87 | $20.2K | 2022-02-28 | SEC |
| 2022-02-25 | S, sale reported on Form 4 | 18 | $4.2K | 2022-02-28 | SEC |
| 2022-02-25 | S, sale reported on Form 4 | 28 | $6.4K | 2022-02-28 | SEC |
| 2022-02-25 | S, sale reported on Form 4 | 115 | $26.6K | 2022-02-28 | SEC |
| 2022-03-17 | S, sale reported on Form 4 | 34 | $8.5K | 2022-03-21 | SEC |
| 2022-03-17 | S, sale reported on Form 4 | 2,799 | $700.0K | 2022-03-21 | SEC |
| 2022-08-09 | S, sale reported on Form 4 | 74 | $22.3K | 2022-08-10 | SEC |
| 2022-08-09 | S, sale reported on Form 4 | 283 | $84.8K | 2022-08-10 | SEC |
| 2022-08-09 | S, sale reported on Form 4 | 72 | $21.6K | 2022-08-10 | SEC |
| 2022-08-09 | S, sale reported on Form 4 | 679 | $202.9K | 2022-08-10 | SEC |
| 2022-08-09 | S, sale reported on Form 4 | 292 | $86.9K | 2022-08-10 | SEC |
| 2023-02-13 | S, sale reported on Form 4 | 64 | $19.2K | 2023-02-14 | SEC |
| 2023-02-13 | S, sale reported on Form 4 | 11 | $3.3K | 2023-02-14 | SEC |
| 2023-02-13 | S, sale reported on Form 4 | 120 | $35.9K | 2023-02-14 | SEC |
| 2023-02-13 | S, sale reported on Form 4 | 78 | $23.3K | 2023-02-14 | SEC |
| 2023-02-13 | S, sale reported on Form 4 | 2 | $592 | 2023-02-14 | SEC |
| 2023-02-14 | S, sale reported on Form 4 | 135 | $40.4K | 2023-02-16 | SEC |
| 2023-02-14 | S, sale reported on Form 4 | 51 | $15.3K | 2023-02-16 | SEC |
| 2023-02-14 | S, sale reported on Form 4 | 43 | $12.8K | 2023-02-16 | SEC |
| 2023-02-14 | S, sale reported on Form 4 | 20 | $5.9K | 2023-02-16 | SEC |
| 2023-02-14 | S, sale reported on Form 4 | 71 | $21.0K | 2023-02-16 | SEC |
| 2023-02-21 | S, sale reported on Form 4 | 124 | $36.6K | 2023-02-22 | SEC |
| 2023-02-21 | S, sale reported on Form 4 | 207 | $60.8K | 2023-02-22 | SEC |
| 2023-02-21 | S, sale reported on Form 4 | 4 | $1.2K | 2023-02-22 | SEC |
| 2023-02-21 | S, sale reported on Form 4 | 145 | $42.5K | 2023-02-22 | SEC |
| 2023-02-27 | S, sale reported on Form 4 | 51 | $14.7K | 2023-02-28 | SEC |
| 2023-02-27 | S, sale reported on Form 4 | 283 | $81.3K | 2023-02-28 | SEC |
| 2023-02-27 | S, sale reported on Form 4 | 20 | $5.8K | 2023-02-28 | SEC |
| 2023-08-10 | S, sale reported on Form 4 | 5,750 | $2.0M | 2023-08-14 | SEC |
| 2023-08-23 | S, sale reported on Form 4 | 2,500 | $887.5K | 2023-08-25 | SEC |
| 2024-02-12 | S, sale reported on Form 4 | 314 | $132.0K | 2024-02-13 | SEC |
| 2024-02-20 | S, sale reported on Form 4 | 480 | $202.0K | 2024-02-21 | SEC |
| 2024-02-21 | S, sale reported on Form 4 | 360 | $151.8K | 2024-02-23 | SEC |
| 2024-02-26 | S, sale reported on Form 4 | 354 | $150.7K | 2024-02-27 | SEC |
| 2024-05-30 | S, sale reported on Form 4 | 2,350 | $1.0M | 2024-06-03 | SEC |
| 2024-05-31 | S, sale reported on Form 4 | 2,250 | $1.0M | 2024-06-03 | SEC |
| 2024-06-03 | S, sale reported on Form 4 | 2,175 | $1.0M | 2024-06-05 | SEC |
| 2025-02-11 | S, sale reported on Form 4 | 310 | $142.5K | 2025-02-12 | SEC |
| 2025-02-18 | S, sale reported on Form 4 | 244 | $111.0K | 2025-02-19 | SEC |
| 2025-02-25 | S, sale reported on Form 4 | 354 | $170.3K | 2025-02-26 | SEC |
| 2025-02-27 | S, sale reported on Form 4 | 530 | $251.9K | 2025-02-28 | SEC |
| 2025-03-04 | S, sale reported on Form 4 | 4,058 | $2.0M | 2025-03-06 | SEC |
| 2025-03-10 | S, sale reported on Form 4 | 3,242 | $1.6M | 2025-03-12 | SEC |
| 2025-12-03 | S, sale reported on Form 4 | 4,500 | $2.0M | 2025-12-05 | SEC |
| 2026-01-07 | S, sale reported on Form 4 | 4,500 | $2.1M | 2026-01-09 | SEC |
| 2026-02-11 | S, sale reported on Form 4 | 466 | $214.6K | 2026-02-12 | SEC |
| 2026-02-13 | S, sale reported on Form 4 | 1,500 | $750.0K | 2026-02-18 | SEC |
| 2026-02-17 | S, sale reported on Form 4 | 609 | $298.1K | 2026-02-19 | SEC |
| 2026-02-18 | S, sale reported on Form 4 | 368 | $174.3K | 2026-02-19 | SEC |
| 2026-02-25 | S, sale reported on Form 4 | 260 | $126.5K | 2026-02-26 | SEC |
| 2026-07-02 | S, sale reported on Form 4 | 1,500 | $787.5K | 2026-07-07 | SEC |
VERV
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
Odyssey Therapeutics, Inc. (ODTX)
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
Counted from the Form 4 filings this reporting owner (SEC CIK 1789815) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.
